DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis

The concept of using BH3 mimetics as anticancer agents has been substantiated by the efficacy of selective drugs, such as Navitoclax and Venetoclax, in treating BCL-2-dependent haematological malignancies. However, most solid tumours depend on MCL-1 for survival, which is highly amplified in multipl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell Death Dis
Autors principals: Milani, Mateus, Byrne, Dominic P, Greaves, Georgia, Butterworth, Michael, Cohen, Gerald M, Eyers, Patrick A, Varadarajan, Shankar
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2017
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5386385/
https://ncbi.nlm.nih.gov/pubmed/28079887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2016.485
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars